论文部分内容阅读
目的研究胶质瘤中骨桥蛋白(OPN)mRNA表达及其临床意义。方法应用半定量RT-PCR法检测OPNmRNA在60例胶质瘤及相应正常脑组织中的表达及相对含量,分析其与胶质瘤临床病理特征和预后之间的关系。结果本组OPNmRNA的阳性表达率为73.3%(44/60),正常脑组织OPNmRNA表达均为阴性,OPNmRNA的相对表达量与肿瘤临床病理分级有关;所有患者平均随访12个月,OPN表达阳性组44例中复发36例,表达阴性组16例中仅复发2例(P<0.05),此外表达阳性组中死亡23例,表达阴性组仅2例死亡(P<0.05)。结论胶质瘤中骨桥蛋白mRNA表达明显增高,并与肿瘤临床病理分级密切相关,骨桥蛋白可作为一临床评价胶质瘤患者预后的良好指标。
Objective To study the expression of osteopontin (OPN) mRNA in gliomas and its clinical significance. Methods The expression and relative content of OPN mRNA in 60 gliomas and corresponding normal brain tissues were detected by semi-quantitative RT-PCR. The relationship between the expression of OPN mRNA and clinicopathological characteristics and prognosis of gliomas was analyzed. Results The positive expression rate of OPN mRNA in this group was 73.3% (44/60), and the expression of OPN mRNA in normal brain tissue was negative. The relative expression of OPN mRNA was correlated with the clinicopathological grade. All patients were followed up for an average of 12 months and the OPN expression was positive Of the 44 cases, 36 cases relapsed, and only 16 cases were negative (P <0.05). In addition, 23 cases were dead and 23 cases were negative (P <0.05). Conclusion The expression of osteopontin mRNA in glioma is significantly increased, which is closely related to the clinicopathological grade of glioma. Osteopontin can be used as a good indicator to evaluate the prognosis of patients with glioma.